Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for TMO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for TMO and 80,000+ other tickers.
See exactly how TMO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for TMO and 80,000+ other tickers.
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the…
Andra AP fonden raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 1,411.9% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 57,814 shares of the medical research company's stock after acquiring an additional 53,990 shares during the
Evaluate the expected performance of Thermo Fisher (TMO) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
AIA Group Ltd lowered its position in Thermo Fisher Scientific Inc. (NYSE: TMO) by 6.2% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 86,693 shares of the medical research company's stock after selling 5,759 shares during
TMO readies for second-quarter 2026 earnings, with growth expected across key segments as bioproduction, clinical research and new launches support results.
On July 13, 2026, we present a detailed DCF analysis for Thermo Fisher Scientific Inc (TMO), a company currently priced at $527.05. Despite a year-to-date decli